Evidence map›Paper›PMID 42130064›Full record

ArticleCancer medicine2026

Exploring Resistance to ETS Targeting Agents in Diffuse Large B-Cell Lymphoma.

Filippo Spriano, Luciano Cascione, Chiara Tarantelli, Giulio Sartori, Alberto J Arribas, Adriana Velasova, Sara Napoli, Ondrej Havranek, Jeffrey A Toretsky, Francesco Bertoni

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Filippo SprianoInstitute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland.
Luciano CascioneInstitute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland.
Chiara TarantelliInstitute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland.
Giulio SartoriInstitute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland.
Alberto J ArribasInstitute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland.
Adriana VelasovaInstitute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland.
Sara NapoliInstitute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland.
Ondrej HavranekBiocev, First Faculty of Medicine, Charles University, Prague, Czech Republic.
Jeffrey A ToretskyDepartments of Oncology and Pediatrics, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.
Francesco BertoniInstitute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland.ORCID https://orcid.org/0000-0001-5637-8983

Funding

Hyundai Hope on Wheels Professorship in Pediatric OncologyLeukemia and Lymphoma Society #6521-17
6 · The paper itself

Abstract

Diffuse large B-cell lymphoma (DLBCL) remains a challenging disease with limited therapeutic options beyond standard immunochemotherapy. ETS transcription factors, including SPIB and SPI1, are implicated in lymphoma pathogenesis and can be targeted by the small molecule TK216, which disrupts ETS-DHX9 interactions. To explore mechanisms of resistance, we generated stable TK216-resistant clones from the ABC-DLBCL line U2932. Resistant clones exhibited a 4-5-fold increase in IC

Indexed as

Antineoplastic AgentsLymphoma, Large B-Cell, DiffuseProto-Oncogene Proteins c-etsAntineoplastic Combined Chemotherapy ProtocolsCell Line, TumorDrug Resistance, NeoplasmDrug Screening Assays, AntitumorG2 Phase Cell Cycle CheckpointsGene Expression Regulation, NeoplasticHumansMutationAntineoplastic AgentsProto-Oncogene Proteins c-etsdiffuse large B‐cell lymphomaETSMDRresistancevenetoclaxXPO1

Identifiers

PMID42130064
PMCPMC13172266

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.